The BioHub: The Top Voices in Biotech

• Steve Butts - CEO Arrivo Bio at BIO Boston 2025

  From BIO Boston: Steve Butts, CEO of Arrivo BioVenturesIn this episode, I sit down with Steve Butts — a five-time biotech founder and the CEO of Arrivo BioVentures.Steve has built and exited multiple companies, and now he's applying everything he’s learned to build Arrivo with precision: lean, capital-efficient, and structured for smart growth.We talk about:— How to build programs that big pharma wants— Why Arrivo structures its assets in separate subsidiaries— Navigating the current market as a small, focused team— And the mindset it takes to keep building in tough conditionsSteve’s approach is clear, disciplined, and proven — this is biotech company-building done right.This episode is part of a series of in-person interviews from BIO Boston with some of the sharpest leaders in the industry.More to come.

  --------  

  9:46

  --------

  9:46
• Alex Blyth - CEO LifT Biosciences at BIO Boston 2025

  From BIO Boston: Alex Blyth, CEO of LifT BiosciencesIn this powerful opening episode from BIO 2025, I sit down with Alex Blyth, the founder and CEO of LifT Biosciences — a company re-engineering the immune system to finally beat cancer at its own game.We talk about:Why targeted therapies are failing most patientsWhat tumour escape is and why it’s the real enemyHow LiFt’s “super neutrophils” could be the Keytruda of innate immunityAnd the personal loss that pushed Alex to rethink everything we know about cancer treatmentAlex’s story is sharp, ambitious, and deeply personal — exactly the kind of leadership biotech needs right now.This is the first in a series of in-person interviews from BIO Boston with some of the sharpest founders and execs in the industry. Stay tuned — more to come.

  --------  

  15:37

  --------

  15:37
• The BioHub - Avetix Podcast - S2 Ep53 - Lisa DiPaolo - Chief Human Resources Officer at Karyopharm

  Lisa DiPaolo is the Executive Vice President and Chief Human Resources Officer at Karyopharm Therapeutics, where she brings over two decades of HR leadership in the pharmaceutical and biotech industries. Since joining Karyopharm in September 2022, she has led the company’s People & Culture strategy through a critical period of growth and transformation. Before this, Lisa served as SVP of HR at Ipsen, overseeing North America as well as global R&D and Business Development, where she drove significant organizational and cultural shifts. She also spent eight years at Biogen in a series of senior roles, including leadership of global therapeutic operations, executive search, and medical affairs HR. Her earlier career included HR leadership roles at Smiths Medical and nearly a decade at Novartis, managing both U.S. and global teams. Lisa holds a B.A. from Montclair State University and an M.S. in Human Resource Management from Rutgers University. Known for her focus on authentic leadership, culture-driven transformation, and scalable HR systems, she is passionate about creating resilient, people-centric organizations that align business goals with strong employee experience.

  --------  

  21:04

  --------

  21:04
• Episode 52– Aaron Royston - Managing Partner at VenBio

  Dr. Aaron Royston, M.D., M.B.A., is a Managing Partner at venBio, a life sciences venture capital firm, where he brings over 15 years of experience in biotechnology investing, company formation, and clinical research. His leadership has contributed to the launch and growth of several successful biotech companies, including Apellis Pharmaceuticals, Ventyx Biosciences, Akero Therapeutics, Harmony Biosciences, and RayzeBio, collectively achieving multiple FDA drug approvals. Before joining venBio, Dr. Royston was part of the investment team at Vivo Capital and worked at Bain & Company, advising biotechnology firms on strategic and operational matters. He began his career coordinating clinical research at Mount Sinai Medical Center, with his work published in various medical journals. Dr. Royston holds a B.S. in Biological Sciences from Duke University and earned both his M.D. and M.B.A. from the University of Pennsylvania. As a student, he founded a technology company that was later acquired, earning him recognition from the White House in 2010 as a Champion of Change for his contributions to technology and innovation. In addition to his role at venBio, Dr. Royston serves on the boards of multiple biotech companies, including Candid Therapeutics, Attovia Therapeutics, 35 Pharma, and ViceBio.

  --------  

  26:56

  --------

  26:56
• Episode 51 – Harith Rajagopalan - CEO & CO-Founder Fractyl Health

  Dr. Harith Rajagopalan is the Co-founder and CEO of Fractyl Health, a company he launched while serving as an Entrepreneur-in-Residence at General Catalyst Partners. Before founding Fractyl, Dr. Rajagopalan was an academic cardiologist and physician-scientist. He earned his B.S. in Chemistry from Stanford University and obtained both M.D. and Ph.D. degrees from Johns Hopkins School of Medicine. At Johns Hopkins, he conducted award-winning research on intestinal cancers, with findings published in leading journals such as Nature and Science. Following medical school, he completed his residency in internal medicine and fellowship in clinical cardiology at Brigham and Women’s Hospital, along with a research fellowship at the Harvard Stem Cell Institute. Under Dr. Rajagopalan's leadership, Fractyl Health has developed innovative therapies targeting metabolic diseases. Notably, the company is advancing Rejuva®, a gene therapy platform designed for long-term remission of obesity and type 2 diabetes by altering metabolic hormone function in pancreatic islet cells. Rejuva is expected to enter first-in-human studies in the first half of 2025.

  --------  

  21:08

  --------

  21:08

Plus de podcasts Sciences

Podcasts tendance de Sciences

À propos de The BioHub: The Top Voices in Biotech